Edgewise Therapeutics, Inc.
EWTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Edgewise Therapeutics, Inc. (EWTX) is listed under Biotechnology. At a $4.28B market cap, Edgewise Therapeutics, Inc. ranks as a mid-cap company within healthcare. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Market Cap
$4.28B
Beta
0.28
P/E (TTM)
—
P/E (Fwd)
-26.13
EPS (TTM)
$-1.73
EPS (Fwd)
$-1.52
ROE
-38.1%
ROA
-25.6%
Cash
$499.6M
Total Debt
$3.8M
Free CF
-$90.5M
52W Change
193.7%
Annual Financials
Cash vs Debt
With $499.6M in cash and $3.8M in debt, EWTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$90.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -38.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
EWTX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, EWTX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Edgewise Therapeutics, Inc. and its sector.